Phase 3 Readout~month

Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Ef

Indication
Non-obstructive Hypertrophic Cardiomyopathy; Obstructive Cardiomyopathy, Hypertrophic

Other upcoming events for LXRX

Patent ExpiryPatent/Exclusivity Expiry: INPEFA

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Ef — LXRX Phase 3 Readout | BioSniper